New Lead Holdings Ltd (NASDAQ:NEWL) soared on Friday after the international shipping company announced it would purchase two bulk carriers for $37.0 million. The company has agreed to buy two eco-type 31,800 deadweight tonnage Handysize bulk carriers built in 2012. New Lead expects delviery of the two vessels by the end of June and July. Upon their receipt, New Lead would own five dry-bulk vessels, including three Handysize and two Panamax vessels.
New Lead Holdings Ltd (NASDAQ:NEWL) shares after opening at $ -31.17 moved to $ on last trade day and at the end of the day closed at $1.07. Company price to sales ratio in past twelve months was calculated as 0.18. New Lead Holdings Ltd (NASDAQ:NEWL) showed a negative weekly performance of -35.93%.
Prana Biotechnology Limited (NASDAQ:PRAN) was downgraded by MLV & Co. from a “buy” rating to a “hold” rating in a research note issued on Monday, Analyst Ratings Network reports. They currently have a $3.00 price target on the stock, down from their previous price target of $11.00. MLV & Co.‘s price target suggests a potential upside of 30.43% from the company’s current price. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares fell -4.13% in last trading session and ended the day on $2.32. PRAN return on equity ratio is recorded as -143.60% and its return on assets is -113.60%. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) yearly performance is 3.11%.
Channel Advisor Corporation (NYSE:ECOM), a leading provider of cloud-based e-commerce solutions that enable retailers and manufacturers to increase global sales, announced its participation in Demand ware’s 2014 X Change Conference and Magento’s Imagine e Commerce Conference. Channel Advisor Corp (NYSE:ECOM) shares moved down -9.93 % in last trading session and was closed at $31.29, while trading in range of $ 30.52 – 35.32. Channel Advisor Corp (NYSE:ECOM) year to date (YTD) performance is -24.98%.
Onconova Therapeutics Inc. (ONTX) share price has entered into oversold territory with an RSI value of 19.3. The Zacks Consensus Estimate for Onconova for the full year period has improved 75 cents over the past two months to $-2.09 per share. Currently, Onconova has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on (ONTX) after its recent drop. Onconova Therapeutics Inc (NASDAQ:ONTX) weekly performance is -9.68%. On last trading day company shares ended up $57. Onconova Therapeutics Inc (NASDAQ:ONTX) distance from 50-day simple moving average (SMA50) is -43.12%. Analysts mean target price for the company is $11.50.